利拉鲁肽联合二甲双胍治疗Ⅱ型糖尿病伴肥胖患者的效果观察

Effects of Liraglutide combined with Metformin in treatment of type 2 diabetes with obesity

目的:观察利拉鲁肽联合二甲双胍治疗Ⅱ型糖尿病伴肥胖患者的效果。方法:将102例Ⅱ型糖尿病伴肥胖患者按照随机数字表法分为研究组和对照组,各51例。对照组予二甲双胍口服治疗,研究组在对照组的基础上加用利拉鲁肽皮下注射治疗,两组均治疗16周。对比两组患者治疗前后的体质指数(BMI)、脂质水平[三酰甘油(TG)、高密度脂蛋白(HDL-C)和低密度脂蛋白(LDL-C)]、血糖水平[空腹血糖水平(FBG)、餐后2 h血糖水平(2 h PG)和糖化血红蛋白水平(HbA1c)]和低血糖发生率。结果:经16周治疗,两组患者BMI、脂质水平和血糖水平均较治疗前改善,且研究组BMI、TG、LDL-C水平及各血糖指标水平低于对照组,HDL-C水平高于对照组,差异均有显著统计学意义(P<0.01);研究组低血糖发生率低于对照组(P<0.05)。结论:利拉鲁肽联合二甲双胍治疗Ⅱ型糖尿病伴肥胖患者的效果优于单纯二甲双胍口服治疗。

Objective: To explore effects Liraglutide combined with Metformin in treatment of type 2 diabetes with obesity. Methods: 102 patients with type 2 diabetes with obesity were divided into study group and control group according to the random number table method, 51 cases in each. The control group was treated with Metformin orally, while the study group was treated with subcutaneous injection of Liraglutide on the basis of that of the control group. Both groups were treated for 16 cycles. The body mass index(BMI), lipid levels [triglyceride(TG), high-density lipoprotein(HDL-C) and low-density lipoprotein(LDL-C,)], blood glucose levels [fasting Blood glucose levels(FBG), postprandial 2 h blood glucose levels(2 hPG) and glycated hemoglobin levels(HbA1 c)] and hypoglycemia rate were compared between the two groups. Results: 16 weeks after the treatment, the BMI, lipid levels, and blood glucose levels were improved in the two groups. The levels of BMI, TG, LDL-C and blood glucose levels in the study group were lower than those in the control group, the HDL-C level was higher than that in the control group(P<0.01), the incidence of hypoglycemia was lower than that in the control group, and the differences were statistically significant(P<0.05). Conclusions: Liraglutide combined with Metformin in the treatment of type 2 diabetes with obesity is superior to single Metformin.